-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ATL-1102 in Duchenne Muscular Dystrophy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ATL-1102 in Duchenne Muscular Dystrophy report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ATL-1102 in Duchenne Muscular Dystrophy Drug Details: ATL-1102, (TV-1102, ISIS...
-
Product Insights
Relapsing Remitting Multiple Sclerosis (RRMS) – Drugs In Development, 2023
Global Markets Direct’s, ‘Relapsing Remitting Multiple Sclerosis (RRMS) - Drugs In Development, 2023’, provides an overview of the Relapsing Remitting Multiple Sclerosis (RRMS) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Relapsing Remitting Multiple Sclerosis (RRMS), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
Recessive X Chromosome Disorders – Drugs In Development, 2023
Global Markets Direct’s, ‘Recessive X Chromosome Disorders - Drugs In Development, 2023’, provides an overview of the Recessive X Chromosome Disorders pipeline landscape. The report provides comprehensive information on the therapeutics under development for Recessive X Chromosome Disorders, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Duchenne Muscular Dystrophy – Drugs In Development, 2023
Global Markets Direct’s, ‘Duchenne Muscular Dystrophy - Drugs In Development, 2023’, provides an overview of the Duchenne Muscular Dystrophy pipeline landscape. The report provides comprehensive information on the therapeutics under development for Duchenne Muscular Dystrophy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Muscular Dystrophy – Drugs In Development, 2023
Global Markets Direct’s, ‘Muscular Dystrophy - Drugs In Development, 2023’, provides an overview of the Muscular Dystrophy pipeline landscape. The report provides comprehensive information on the therapeutics under development for Muscular Dystrophy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Limb-Girdle Muscular Dystrophy – Drugs In Development, 2023
Global Markets Direct’s, ‘Limb-Girdle Muscular Dystrophy - Drugs In Development, 2023’, provides an overview of the Limb-Girdle Muscular Dystrophy pipeline landscape. The report provides comprehensive information on the therapeutics under development for Limb-Girdle Muscular Dystrophy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Acromegaly – Drugs In Development, 2023
Global Markets Direct’s, ‘Acromegaly - Drugs In Development, 2023’, provides an overview of the Acromegaly pipeline landscape. The report provides comprehensive information on the therapeutics under development for Acromegaly, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Vopratelimab in Triple-Negative Breast Cancer (TNBC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Vopratelimab in Triple-Negative Breast Cancer (TNBC) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Vopratelimab in Triple-Negative Breast Cancer (TNBC) Drug Details: Vopratelimab (JTX-2011)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ATL-1102 in Duchenne Muscular Dystrophy
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. ATL-1102 in Duchenne Muscular Dystrophy Drug Details: ATL-1102, (TV-1102, ISIS 107248) is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Fesomersen Sodium in End-Stage Kidney Disease (End-Stage Renal Disease or ESRD)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Fesomersen Sodium in End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Fesomersen Sodium in End-Stage Kidney Disease...